TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) shares traded down 4.9% during trading on Wednesday . The company traded as low as $125.52 and last traded at $129.51. 418,244 shares traded hands during trading, a decline of 69% from the average session volume of 1,357,738 shares. The stock had previously closed at $136.20.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on TMDX shares. Piper Sandler reiterated an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Tuesday. Finally, Oppenheimer boosted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $127.33.
View Our Latest Stock Analysis on TMDX
TransMedics Group Price Performance
The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. The firm's 50-day moving average price is $114.23 and its two-hundred day moving average price is $84.05. The stock has a market cap of $4.18 billion, a PE ratio of 90.85 and a beta of 2.10.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. TransMedics Group's revenue was up 48.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.35 earnings per share. On average, equities analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.
Insider Buying and Selling at TransMedics Group
In other news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider now directly owns 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of the stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares of the company's stock, valued at $84,641.16. The trade was a 89.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,418 shares of company stock worth $1,512,613 over the last quarter. Insiders own 7.00% of the company's stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after buying an additional 2,209,996 shares during the period. Goldman Sachs Group Inc. raised its stake in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after acquiring an additional 86,721 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock worth $1,314,000 after acquiring an additional 868 shares during the last quarter. Royal Bank of Canada lifted its position in TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock worth $1,788,000 after acquiring an additional 8,604 shares during the period. Finally, Quarry LP grew its stake in TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.